Bristol-Myers Squibb (NYSE:BMY) Holdings Trimmed by Ropes Wealth Advisors LLC

Ropes Wealth Advisors LLC trimmed its position in shares of Bristol-Myers Squibb (NYSE:BMYGet Rating) by 15.3% during the 4th quarter, HoldingsChannel reports. The firm owned 56,362 shares of the biopharmaceutical company’s stock after selling 10,173 shares during the quarter. Ropes Wealth Advisors LLC’s holdings in Bristol-Myers Squibb were worth $3,514,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of BMY. OLD Mission Capital LLC acquired a new stake in shares of Bristol-Myers Squibb during the 3rd quarter valued at $234,000. EagleClaw Capital Managment LLC boosted its stake in shares of Bristol-Myers Squibb by 2.9% during the 3rd quarter. EagleClaw Capital Managment LLC now owns 64,447 shares of the biopharmaceutical company’s stock valued at $3,823,000 after buying an additional 1,800 shares during the period. Massachusetts Financial Services Co. MA boosted its stake in shares of Bristol-Myers Squibb by 541.0% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 42,160 shares of the biopharmaceutical company’s stock valued at $2,495,000 after buying an additional 35,583 shares during the period. O Shaughnessy Asset Management LLC boosted its stake in shares of Bristol-Myers Squibb by 14.6% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 280,630 shares of the biopharmaceutical company’s stock valued at $16,605,000 after buying an additional 35,851 shares during the period. Finally, Rafferty Asset Management LLC boosted its holdings in Bristol-Myers Squibb by 54.5% in the third quarter. Rafferty Asset Management LLC now owns 82,990 shares of the biopharmaceutical company’s stock worth $4,911,000 after purchasing an additional 29,273 shares in the last quarter. 73.07% of the stock is owned by institutional investors.

A number of equities research analysts recently issued reports on BMY shares. Guggenheim upped their price objective on shares of Bristol-Myers Squibb from $72.00 to $80.00 in a report on Monday, May 2nd. Truist Financial upped their price target on shares of Bristol-Myers Squibb from $76.00 to $81.00 in a report on Monday, May 2nd. Morgan Stanley cut their price objective on shares of Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating for the company in a research report on Wednesday, April 6th. StockNews.com began coverage on shares of Bristol-Myers Squibb in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Finally, BMO Capital Markets increased their price target on shares of Bristol-Myers Squibb from $87.00 to $92.00 in a research report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $71.33.

Shares of BMY traded down $0.50 during mid-day trading on Friday, hitting $75.80. 13,773,108 shares of the company’s stock were exchanged, compared to its average volume of 14,853,342. Bristol-Myers Squibb has a 52 week low of $53.22 and a 52 week high of $78.17. The stock’s 50-day simple moving average is $74.15 and its 200-day simple moving average is $66.36. The firm has a market cap of $161.38 billion, a price-to-earnings ratio of 26.88, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. The company has a quick ratio of 1.23, a current ratio of 1.32 and a debt-to-equity ratio of 1.18.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last posted its earnings results on Friday, April 29th. The biopharmaceutical company reported $1.96 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.05. The firm had revenue of $11.65 billion for the quarter, compared to analysts’ expectations of $11.34 billion. Bristol-Myers Squibb had a net margin of 13.31% and a return on equity of 48.37%. The company’s revenue was up 5.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 earnings per share. Analysts forecast that Bristol-Myers Squibb will post 7.57 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Monday, May 2nd. Shareholders of record on Friday, April 1st were paid a dividend of $0.54 per share. The ex-dividend date was Thursday, March 31st. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.85%. Bristol-Myers Squibb’s payout ratio is presently 76.60%.

In other news, EVP Rupert Vessey sold 74,559 shares of Bristol-Myers Squibb stock in a transaction on Wednesday, March 16th. The shares were sold at an average price of $69.25, for a total transaction of $5,163,210.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Giovanni Caforio sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Monday, March 21st. The stock was sold at an average price of $71.52, for a total transaction of $1,788,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 165,668 shares of company stock worth $11,459,888. Insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Profile (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Featured Articles

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYGet Rating).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.